deltatrials
Completed PHASE2 INTERVENTIONAL NCT00417573

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Sponsor: Grifols Therapeutics LLC

Conditions IgG Deficiency Infections
Interventions IV Gamunex 10%
Updated 6 times since 2017 Last updated: Dec 29, 2006 Started: Dec 31, 2004 Completion: Dec 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates IgG Deficiency and Infections and is currently completed. Grifols Therapeutics LLC leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Apr 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grifols Therapeutics LLC
  • The Center for Rheumatic Disease, Allergy, & Immunology
Data source: The Center for Rheumatic Disease, Allergy, & Immunology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations